CENTIZYME

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.